Complimentary Download: Is the PTO Review Board a ‘Death Squad’ or Not? The Evolution of Inter Partes Review for Biopharma Patents

REGISTER NOW

Over the last several years, the PTO’s inter partes review (IPR) process has garnered a reputation among some patent holders for canceling many rightly-approved biopharma patent claims. While the process does provide a pathway for challenging patents – including biopharma patents –  that are deemed unfounded, the reality is the ratio of patents invalidated to patents that survive the IPR process has shifted, with more now surviving than being canceled.

Download Bloomberg Law’s expertly crafted report, Is the PTO Review Board a ‘Death Squad’ or Not? The Evolution of Inter Partes Review for Biopharma Patents, now and you will get an analysis of the background of the process as well as a detailed analysis of the evolution of the process from its inception in 2012.

Download the report now and get:

  • Expert perspectives from judges, biopharma attorneys and key industry players on how the process has impacted their work and potential future implications.
  • Understand some of the more controversial IPR filings, including those from hedge funds and organizations related to them, which precipitated the -- currently-stalled -- congressional action to tighten requirements for who could file a petition to initiate an IPR.
  • Monitor slowing trend of IPRs as challenges to biopharma patents for the first four months of 2016 have declined 25 percent from those filed for the same period in 2015 and how this trend may impact the process further.
  • Snapshot highlights of PTAB judgments in IPR cases that involve biopharma patents and how these outcomes might signal an evolution in the IPR process.

Download Now